Abstract
Ovarian cancer is the fourth most common cause of cancer-related death in women, but is the most lethal of the gynaecological malignancies with 30–40% overall survival at 5 years [1]. This is in part because the majority of patients with ovarian cancer present with advanced disease, and treatment options at presentation are confined to a combination of debulking surgery and platinum based chemotherapy, which are only partially effective [2]. Consequently, almost all patients with advanced disease ultimately relapse and die of their disease. Advances in the management of these patients are therefore urgently required.

This publication has 17 references indexed in Scilit: